Oncology Pharma Inc.
20.7.2021 13:32:38 CEST | ACCESS Newswire | Press release
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat clinical trials ("Mouse clinical trials" or "MCT") all steps are being established. The Company has decided to pursue moving forward with MCT as it most closely represents the setting of a human clinical trial.
Human preclinical methods are different as they use a small number of models with a large number of tests per subject. Mouse clinical trials tend to upend the traditional preclinical paradigm and better resemble and match the actual clinical setting. The Company believes this is an effective and cost-efficient way of moving forward. Utilizing MCTs will develop data that can be leveraged for biomarker discovery, which is ever more crucial for clinical trial success.
In addition, the Company continues to develop its business model to support the currently licensed IP and providing them with the necessary tools each individual licensor needs to support their individual business so they can contribute to the business plan of Oncology Pharma, Inc.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/656221/Oncology-Pharma-Inc-To-Move-to-Conducting-Trials-on-Licensed-IP
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Merchant Payments Ecosystem Announces Winners of the MPE Awards 202627.3.2026 12:00:00 CET | Press release
Industry leaders, innovators and emerging companies were recognized in Berlin for excellence across the merchant payments ecosystem. BERLIN, GERMANY / ACCESS Newswire / March 27, 2026 / Merchant Payments Ecosystem (MPE) today announced the winners of the MPE Awards 2026, recognizing the companies and individuals driving innovation, leadership and measurable impact across the merchant payments value chain. Presented during the MPE Awards Gala in Berlin on March 18, the annual awards celebrated excellence across payment acceptance, orchestration, embedded finance, open banking, fraud and compliance, identity, settlement, merchant-led innovation and more. With 177 entries submitted this year, the MPE Awards 2026 highlighted the scale, competitiveness and diversity of innovation shaping the future of merchant payments. The central theme of this year's awards was "Transformation through Trust & Resilience." "The MPE Awards 2026 winners demonstrate that the future of merchant payments will b
RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation27.3.2026 11:00:00 CET | Press release
All amounts in CAD dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / March 27, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") today announced that its Board of Directors (the "Board") has initiated a formal review of strategic alternatives (the "Strategic Review") to identify opportunities to maximize value for shareholders. As part of this process, the Board will evaluate a broad range of potential alternatives, including, but not limited to, a sale of the Company, strategic or co-investment partnerships, or capital structure optimizations through equity or debt financings. The Strategic Review represents a natural evolution for RE Royalties as the Company enters its 11th year of operations and seeks to position itself for future growth. The Strategic Review follows a formal recommendation from management. A Special Committee of the Board ("Special Committee") has been established to lead the process and oversee the evaluati
Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project26.3.2026 22:00:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / March 26, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to provide an update on its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Company Financing update The Company has been approved for up to $200,000 in government funding as part of the Ontario Junior Exploration Program (OJEP) that will be used to advance work in the 2.5 km long Escape down-plunge target, where it recently intersected 53m of resource-grade mineralization in the initial exploration hole (Figure 1 and October 20, 2025 release). "Ontario is leading the charge to secure the minerals that will power our economy and strengthen our sovereignty," said Stephen Lecce, Minister of Energy and Mines. "Through OJEP, we're backing companies like Clean Air Metals Inc. to advance promising projects here at home-unlocking resources, creating jobs, and building a more self-reliant and secure
LHH 2026 C-Suite Research: Executive Turnover Falls Sharply as AI Accountability and Decision-Making Gaps Define Leadership Agenda26.3.2026 17:05:00 CET | Press release
High-turnover leadership teams drop from 43% to 19% year-over-year; AI identified as the #1 executive skill gap. NEW YORK CITY, NY / ACCESS Newswire / March 26, 2026 / LHH, the integrated professional talent solutions provider and global business unit of the Adecco Group, released its 2026 View from the C-Suite report, examining executive priorities, leadership skill gaps, and organizational performance internationally. The report highlights a notable shift in the executive landscape: while turnover is falling, the expectations and pressures on leaders are intensifying across technology, decision-making, and talent strategy. Brief The annual View from the C-Suite report finds that executive turnover is declining significantly. Leaders are navigating high external pressures, including economic uncertainty, market volatility, inflation, rising costs, and heightened data security risks. Internal priorities are increasingly focused on talent retention, team effectiveness, and employee well
Multi-Billion-Dollar Sports Brand U.S. Polo Assn. Launches Global Polo Shirt Campaign: An Icon Born from the Game26.3.2026 12:00:00 CET | Press release
WEST PALM BEACH, FLA. / ACCESS Newswire / March 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.1. U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the Game 2. U.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina 3. ‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. models The polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for wh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom